Kisspeptin-10

01 · What it is

Anti-doping laboratories have built and validated a urine test for kisspeptin-10. That fact establishes both what the compound does and who the testing community expects to encounter using it.

The 2024 paper describing that method opens by stating the pharmacology plainly: kisspeptin-10 is a peptide hormone capable of increasing circulating follicle-stimulating hormone, luteinizing hormone and testosterone levels in humans ¹⁸. The authors then describe validating both a screening procedure and a confirmation procedure by liquid chromatography high-resolution mass spectrometry, and they call it a novel doping-relevant peptide ¹⁸.

What it is. Kisspeptin-10 is a fragment of the KISS1 gene product and the ligand for GPR54, also called KISS1R ⁴. Its position in the endocrine hierarchy is unusually high: humans and mice with GPR54 mutations have hypogonadotropic hypogonadism, characterised by absence of sexual maturation and low gonadotropin levels ⁴. This is the signal that starts puberty.

What administration does. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. Intracerebroventricular administration dose-dependently increased plasma luteinizing hormone and raised follicle-stimulating hormone and total testosterone at 60 minutes ¹.

Why its position in the cascade matters more than its potency. Kisspeptin does not act on the gonads. It acts on the neurons that release gonadotropin-releasing hormone, which drive the pituitary, which drives the gonads. Anything given at that level moves an entire regulatory system rather than a single output, and the system it moves is one that also connects to energy balance ¹⁴, prolactin ¹³, behaviour and emotional processing ¹², bone ¹⁵ and glial signalling ¹⁷.

The compound is a research tool at the top of a cascade, and the honest summary is that its human literature is about physiology rather than therapy.

02 · Evidence at a glance

Evidence grade

Early Clinical — human endocrine effects are attested ¹⁸; no approved indication

What it is

A KISS1-derived peptide; ligand for GPR54 / KISS1R ⁴

Position in the axis

Upstream of GnRH neurons — the signal that initiates puberty ^4,10

Loss-of-function phenotype

GPR54 mutation causes hypogonadotropic hypogonadism with absent sexual maturation ⁴

Human effect

Increases circulating FSH, LH and testosterone ¹⁸

Animal administration data

ICV administration dose-dependently raised LH, with FSH and testosterone increases at 60 min ¹

Anti-doping status

A validated urine screening and confirmation method exists; described as a novel doping-relevant peptide ¹⁸

Beyond reproduction

Energy balance ¹⁴, prolactin regulation ¹³, behaviour and emotion ¹², bone ¹⁵, astrocyte signalling ¹⁷

Clinical genetics

Human kisspeptin-pathway variants produce diverse reproductive phenotypes ⁸

Antagonists developed

Yes ⁷

Approved indication

None identified

Published toxicology

None located

US regulatory status

Not an approved drug; not a lawful dietary supplement ingredient

03 · Mechanism of action

The switch that starts puberty

GPR54 has an essential role in the initiation and maintenance of mammalian fertility, and humans and mice lacking functional receptor fail to undergo sexual maturation and carry low gonadotropin levels ⁴. Kisspeptin signalling is central to pubertal development and its regulation ¹⁰, and to the genetics of puberty more broadly ². Kisspeptin’s role in puberty has been characterised across mammals ⁹.

A molecule whose absence prevents puberty entirely is not a peripheral modulator. It is the input.

What supplying it does

Administered centrally, kisspeptin-10 dose-dependently increased plasma luteinizing hormone and raised follicle-stimulating hormone and total testosterone; peripheral administration also stimulated the axis ¹. In humans, the compound increases circulating FSH, LH and testosterone ¹⁸.

The mechanism is indirect by design. Kisspeptin drives GnRH neurons; GnRH drives the pituitary; the pituitary drives the gonads. Three steps, each with its own regulation, which is why effects on any one hormone depend on where in that chain the system currently sits.

The axis is not only reproductive

Kisspeptin sits at a junction. It links energy balance to reproduction, with metabolic state regulating kisspeptin signalling ¹⁴. It interacts with prolactin ¹³. It has documented roles in behavioural, emotional and cognitive control across species from zebrafish to humans ¹². GPR54 activation by kisspeptin-10 in osteoclasts prevents bone loss through Dusp18-mediated dephosphorylation of Src ¹⁵. Kisspeptin signalling in astrocytes modulates the reproductive axis, with KISS1R expressed in astrocytes from humans, rats and mice ¹⁷.

The bone result is worth pausing on. It was published in Nature Communications in 2024 and concerns a completely different cell type from the one the compound is known for. A hormone with receptors in osteoclasts, astrocytes and hypothalamic neurons has a systemic reach that reproductive framing obscures.

Antagonists exist, which is informative

A body of work has developed kisspeptin antagonists ⁷.

Pharmacologists build antagonists when a system needs to be turned down as well as up. Their existence indicates that excessive signalling through this pathway is a recognised concept, not a hypothetical one.

04 · Key research findings

Administration stimulates the axis, 2004. Intracerebroventricular kisspeptin-10 dose-dependently increased plasma luteinizing hormone, with increased follicle-stimulating hormone and total testosterone at 60 minutes after injection; peripheral administration also stimulated the hypothalamic-pituitary-gonadal axis ¹.

The foundational administration study, and the source of the effect profile that everything since rests on.

The receptor and its loss-of-function phenotype, 2007–2008. Reviews establishing GPR54’s essential role in fertility and the hypogonadotropic hypogonadism seen in humans and mice with receptor mutations ⁴, set alongside the wider genetics of puberty, where at least 17 single-gene mutations were then recognised in disordered human puberty ².

The metabolic connection, 2007 and 2020. Leptin’s role in reproduction and its restoration of neuroendocrine function ³, and a Nature Reviews Endocrinology review of the metabolic regulation of kisspeptin as the link between energy balance and reproduction ¹⁴.

This is why kisspeptin is interesting to endocrinology and why it is not a simple lever. The same signal that reports energy availability gates reproductive function.

The clinical genetics, 2010–2013. Reviews of kisspeptin biology drawing on animal and human studies of idiopathic hypogonadotropic hypogonadism ⁵, of kisspeptin and fertility ⁶, and of the human genetics of kisspeptin signalling across diverse reproductive phenotypes, in a field where the pathways governing GnRH physiology were discovered by studying humans with disorders of GnRH secretion ⁸.

The human evidence base here is genetic and observational — what happens when the system is broken — rather than interventional.

Antagonist development, 2013. A review of kisspeptin antagonists ⁷.

Clinical context, 2016–2018. Reviews of pubertal development and regulation ¹⁰ and of central precocious puberty from genetics to treatment ¹¹.

Behaviour and prolactin, 2019. Kisspeptin as a behavioural hormone, with molecular and neural insights into its role in behavioural, emotional and cognitive control from zebrafish to humans ¹²; and its relationship with prolactin ¹³.

Bone, 2024. Kisspeptin-10 binding GPR54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src at Tyr 416, with GPR54 recruiting both active Src and the Dusp18 phosphatase at a proline/arginine-rich motif in its C-terminus ¹⁵.

A specific, well-characterised mechanism in a tissue outside the reproductive axis, published in a high-profile journal. It is also a reminder that this receptor is present in places the marketing does not mention.

Astrocytes, 2024. A glial-kisspeptin pathway, validated by demonstrated KISS1R expression in mouse astrocytes in vivo and in astrocyte cultures from humans, rats and mice, where kisspeptin activated canonical intracellular signalling pathways; conditional receptor ablation was used to test the pathway’s role ¹⁷.

The anti-doping method, 2024. Validation of an initial testing procedure and a confirmatory procedure for detecting kisspeptin-10 in urine by liquid chromatography high-resolution mass spectrometry, framed explicitly around the compound as doping-relevant on the basis that it raises FSH, LH and testosterone in humans ¹⁸.

This is the single most practically important paper in the guide. A validated urine assay means detection is possible, and the reason it was built is that laboratories expect to encounter the compound.

Species breadth, 2024. Intraperitoneal kisspeptin-10 modulating follicle maturation, gonadal steroids, calcium and metabolites in Sterlet sturgeon ¹⁶.

Current synthesis, 2025. A review of the kisspeptin system’s physiology and clinical perspectives ¹⁹.

05 · Evidence overview

06 · Safety profile

Human data. No dedicated safety study was located. What is established is the pharmacological effect — increases in FSH, LH and testosterone ¹⁸ — and the physiological consequence of the pathway’s absence, which is failure of sexual maturation ⁴.

Animal data. Administration studies report endocrine effects rather than toxicity ^1,16. No toxicology study appears in the material located here.

What is genuinely unknown. Almost everything relevant to administration outside a research setting. No published human pharmacokinetics, dose-finding, repeat-dose toxicology, genotoxicity, carcinogenicity or reproductive toxicity was located.

Three gaps deserve naming. What sustained stimulation of a pulsatile system does. The hypothalamic-pituitary-gonadal axis is regulated by pulse frequency, and continuous stimulation of GnRH signalling is well known in endocrinology to produce downregulation rather than sustained activation — the principle GnRH agonists exploit therapeutically. Nothing in this file characterises what repeated kisspeptin-10 administration does to axis responsiveness over time, and the existence of a kisspeptin antagonist literature ⁷ indicates the field takes over-signalling seriously.

Effects outside reproduction. Receptors in osteoclasts ¹⁵ and astrocytes ¹⁷, plus documented roles in energy balance ¹⁴, prolactin regulation ¹³ and behaviour ¹², mean systemic administration reaches systems no reproductive endpoint would detect.

Fertility and pregnancy. A compound acting at the master switch of the reproductive axis has obvious implications in anyone who might conceive, and nothing located here addresses them.

Nothing is published on the identity or purity of any material sold under this name.

07 · US regulatory status

Current as of 7 September 2026. Kisspeptin-10 is not an approved drug in the United States, is not a controlled substance, and is not a lawful dietary supplement ingredient. No marketing authorisation in any jurisdiction was identified for this guide.

Anti-doping is the live regulatory question here. A validated urine screening and confirmation method for kisspeptin-10 was published in 2024, in work describing it as a novel doping-relevant peptide on the basis of its effects on FSH, LH and testosterone in humans ¹⁸. Whether the compound is currently listed as prohibited is a question for the current WADA Prohibited List, which this guide has not consulted and which competitors should read directly rather than relying on secondary summaries, including this one. The existence of a validated detection method is a fact about laboratory capability, not a statement of prohibited status — but the two are not unrelated.

08 · Limitations of the evidence

1. The human evidence is physiological, not therapeutic. The compound’s effect on gonadotropins is established ¹⁸, and this guide located no interventional trial testing it against a clinical outcome in any condition.

1. It acts at the top of a three-step cascade. Kisspeptin drives GnRH neurons, which drive the pituitary, which drives the gonads ⁴. Effects therefore depend on the state of the whole system, and results in one population do not straightforwardly transfer to another.

1. Pulsatility is central to this axis and unaddressed here. No source located characterises what repeated or sustained administration does to responsiveness over time, in a system where continuous stimulation is the established mechanism for shutting signalling down.

1. The receptor is not confined to the reproductive axis ^15,17, so systemic administration acts on tissues that reproductive endpoints do not measure.

1. No toxicology of any kind was located.

1. The human genetic literature describes loss of function, not gain. GPR54 mutations causing hypogonadotropic hypogonadism ^4,8 establish that the pathway is necessary. They say nothing about the consequences of supplying extra ligand to an intact system.

1. Much of the literature is review, and the primary human data cited here are indirect — a detection-method paper ¹⁸ rather than a clinical study.

1. Fewer than twenty of roughly 903 records were examined, and the selection was weighted toward reviews, mechanism and the anti-doping literature. A different selection would emphasise different things, and that choice is disclosed rather than hidden.

1. This guide has read abstracts, not full texts, for every source cited.

1. Nothing is known about material sold under this name. No published analysis has examined the identity or purity of any kisspeptin-10-labelled product.

09 · References

1. Thompson EL, Patterson M, Murphy KG, Smith KL, Dhillo WS, Todd JF, Ghatei MA, Bloom SR. Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. J Neuroendocrinol. 2004 Oct;16(10):850–858.

   PMID 15500545 ↗

2. Herbison AE. Genetics of puberty. Horm Res. 2007;68 Suppl 5:75–79. Review.

   PMID 18174715 ↗

3. Blüher S, Mantzoros CS. Leptin in reproduction. Curr Opin Endocrinol Diabetes Obes. 2007 Dec;14(6):458–464. Review.

   PMID 17982352 ↗

4. Colledge WH. GPR54 and kisspeptins. Results Probl Cell Differ. 2008;46:117–143. Review.

   PMID 18193176 ↗

5. Hameed S, Dhillo WS. Biology of kisspeptins. Front Horm Res. 2010;39:25–36. Review.

   PMID 20389083 ↗

6. Hameed S, Jayasena CN, Dhillo WS. Kisspeptin and fertility. J Endocrinol. 2011 Feb;208(2):97–105. Review.

   PMID 21084385 ↗

7. Roseweir AK, Millar RP. Kisspeptin antagonists. Adv Exp Med Biol. 2013;784:159–186. Review.

   PMID 23550006 ↗

8. Silveira LG, Latronico AC, Seminara SB. Kisspeptin and clinical disorders. Adv Exp Med Biol. 2013;784:187–199. Review.

   PMID 23550007 ↗

9. Terasawa E, Guerriero KA, Plant TM. Kisspeptin and puberty in mammals. Adv Exp Med Biol. 2013;784:253–273. Review.

   PMID 23550010 ↗

10. Abreu AP, Kaiser UB. Pubertal development and regulation. Lancet Diabetes Endocrinol. 2016 Mar;4(3):254–264. Review.

    PMID 26852256 ↗

11. Aguirre RS, Eugster EA. Central precocious puberty: from genetics to treatment. Best Pract Res Clin Endocrinol Metab. 2018 Aug;32(4):343–354. Review.

    PMID 30086862 ↗

12. Mills EGA, O’Byrne KT, Comninos AN. Kisspeptin as a behavioral hormone. Semin Reprod Med. 2019 Mar;37(2):56–63. Review.

    PMID 31847025 ↗

13. Grattan DR, Szawka RE. Kisspeptin and prolactin. Semin Reprod Med. 2019 Mar;37(2):93–104.

    PMID 31847029 ↗

14. Navarro VM. Metabolic regulation of kisspeptin — the link between energy balance and reproduction. Nat Rev Endocrinol. 2020 Aug;16(8):407–420. Review.

    PMID 32427949 ↗

15. Li Z, Yang X, Fu R, Wu Z, Xu S, Jiao J, Qian M, Zhang L, Wu C, Xie T, Yao J, Wu Z, Li W, Ma G, You Y, Chen Y, Zhang HK, Cheng Y, Tang X, Wu P, Lian G, Wei H, Zhao J, Xu J, Ai L, Siwko S, Wang Y, Ding J, Song G, Luo J, Liu M, Xiao J. Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. Nat Commun. 2024 Feb 12;15(1):1300.

    PMID 38346942 ↗

16. Roosta Z, Unniappan S, Uju C, Rahmati M, Falahatkar B. Intraperitoneal administration of kisspeptin-10 modulates follicle maturation, gonadal steroids, calcium and metabolites in Sterlet sturgeon, Acipenser ruthenus. Comp Biochem Physiol A Mol Integr Physiol. 2024 Jun;292:111609.

    PMID 38401763 ↗

17. Torres E, Pellegrino G, Granados-Rodríguez M, Fuentes-Fayos AC, Velasco I, Coutteau-Robles A, Legrand A, Shanabrough M, Perdices-Lopez C, Leon S, Yeo SH, Manchishi SM, Sánchez-Tapia MJ, Navarro VM, Pineda R, Roa J, Naftolin F, Argente J, Luque RM, Chowen JA, Horvath TL, Prevot V, Sharif A, Colledge WH, Tena-Sempere M, Romero-Ruiz A. Kisspeptin signaling in astrocytes modulates the reproductive axis. J Clin Invest. 2024 Jun 11;134(15):e172908.

    PMID 38861336 ↗

18. Colpaert T, Risseeuw M, Deventer K, Van Eenoo P. Investigating the detection of the novel doping-relevant peptide kisspeptin-10 in urine using liquid chromatography high-resolution mass spectrometry. Biomed Chromatogr. 2024 Sep;38(9):e5946.

    PMID 38978171 ↗

19. Stoynev N, Kumanov P. Kisspeptin system — physiology and clinical perspectives. Ann Endocrinol (Paris). 2025 Jul;86(4):101793. Review.

    PMID 40446957 ↗